Abstract
Although high-frequency deep brain stimulation (DBS) is effective at relieving many motor symptoms of Parkinson’s disease (PD), its effects on gait can be variable and unpredictable. This is due to 1) a lack of standardized and robust metrics for gait assessment in PD patients, 2) the challenges of performing a thorough evaluation of all the stimulation parameters space that can alter gait, and 3) a lack of understanding for impacts of stimulation on the neurophysiological signatures of walking. In this study, our goal was to develop a data-driven approach to identify optimal, personalized DBS stimulation parameters to improve gait in PD patients and identify the neurophysiological signature of improved gait. Local field potentials from the globus pallidus and electrocorticography from the motor cortex of three PD patients were recorded using an implanted bidirectional neural stimulator during overground walking. A walking performance index (WPI) was developed to assess gait metrics with high reliability. DBS frequency, amplitude, and pulse width on the “clinically-optimized” stimulation contact were then systemically changed to study their impacts on gait metrics and underlying neural dynamics. We developed a Gaussian Process Regressor (GPR) model to map the relationship between DBS settings and the WPI. Using this model, we identified and validated personalized DBS settings that significantly improved gait metrics. Linear mixed models were employed to identify neural spectral features associated with enhanced walking performance. We demonstrated that improved walking performance was linked to the modulation of neural activity in specific frequency bands, with reduced beta band power in the pallidum and increased alpha band pallidal-motor cortex coherence synchronization during key moments of the gait cycle. Integrating WPI and GPR to optimize DBS parameters underscores the importance of developing and understanding personalized, data-driven interventions for gait improvement in PD.
Competing Interest Statement
D.D.W. consults for Medtronic, Boston Scientific Corp, and Iota. P.A.S. receives support from Medtronic and Boston Scientific for fellowship education. S.L. consults for Iota Biosciences. H.F., K.H.L., J.E.B., K.N.P., J.P.B., J.H.M., T.A.W., N.B.G., M.S. declare no competing interests.
Clinical Trial
NCT03582891
Funding Statement
This study is supported in part by NIH grant R01NS130183 (R01), MJFF grant MJFF-010435 (MJFF), and the Burroughs Wellcome Fund Career Award for Medical Scientists. All funding was acquired by D.D.W.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants were enrolled in a clinical trial (ClinicalTrials.gov ID: NCT-03582891) at the University of California San Francisco (UCSF), which was approved by the UCSF Institutional Review Board (IRB) under the approval number 20-32847.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
7 Data availability
Data from this study can be made available upon reasonable request, provided that patient confidentiality is maintained and disclosure standards are met.
